52 results about "Bowel obstruction" patented technology

An apparatus and method for reducing post-operative ileus and/or gastric stasis is described. The method can include applying to the intestine a therapeutically effective amount of a composition comprising a drug that is effective in reducing post-operative ileus and/or gastric stasis, such as by introducing the composition through a surgical access device, such as a trocar or endoscope. The apparatus can include a surgical fastener and a buttress comprising the composition.

An apparatus and method for reducing post-operative ileus and/or gastric stasis is described. The method can include applying to the intestine a therapeutically effective amount of a composition comprising a drug that is effective in reducing post-operative ileus and/or gastric stasis, such as by introducing the composition through a surgical access device, such as a trocar or endoscope. The apparatus can include a sheet of material, a surgical fastener, or a buttress comprising the composition.

A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being exposed substantially only to the host's subcutaneous tissue layer. This orientation allows the tissue-ingrowth biodegradable region to become firmly incorporated with the host's body tissue. The adhesion-resistant biodegradable region faces the internal organs and decreases the incidence of adhesions and/or bowel obstruction.

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being exposed substantially only to the host's subcutaneous tissue layer. This orientation allows the tissue-ingrowth biodegradable region to become firmly incorporated with the host's body tissue. The adhesion-resistant biodegradable region faces the internal organs and decreases the incidence of adhesions and/or bowel obstruction.

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.

A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being exposed substantially only to the host's subcutaneous tissue layer. This orientation allows the tissue-ingrowth biodegradable region to become firmly incorporated with the host's body tissue. The adhesion-resistant biodegradable region faces the internal organs and decreases the incidence of adhesions and/or bowel obstruction.

A method of treating a temporary arrest of intestinal peristalsis includes inducing at least one of an electric current, an electric field and an electromagnetic field in a sympathetic nerve chain of a mammal to block and/or modulate inhibitory nerve signals thereof such that intestinal peristalsis function is at least partially improved.

The present invention is directed to imidazolyl derivatives of the formula:

where the substituents are defined in the specification, or a pharmaceutically acceptable salt thereof. The derivatives bind selectively to the somatostatin subtype receptors and elicit either an agonist or antagonist effect from the somatostatin subtype receptors. The derivatives are useful for treating a variety of diseases including acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas.

A Chinese traditional medicine for curing adhesive ileus belongs to the Chinese traditional medicine for curing adhesive ileus. The ingredients of the medicine (with weights) are fried radish seed 45g, immature orange fruit 10g, peach kernel 10g, officinal magnolia 15g, common aucklandia root 10g, nutgrass galingale rhizome 12g, red peony root 10g, rhubarb 20g and sodium sulfate 10g; the auxiliary ingredients include gansui root 1.5g which is taken with water under the situation of much intestines hydrops; monkshood 12g and dried ginger 12g under the situation of cold syndrome; the red peony root is removed and the rhubarb and sodium sulfate are increased twice under the situation of dyspepsia; the peony is removed and the officinal magnolia and the common aucklandia root are increased twice under the situation of qi stagnation. The medicines used in the prescription are all natural herbs and the Chinese traditional medicine is processed with traditional method; the fetching of material is convenient and the prescription and manufacture method are simple; the expense for manufacturing the medicine is low. The composition of the Chinese herbal medicine is simple and the medicines used in the prescription are all natural ones and the fetching and use are convenient; the manufacture method is simple and the effect is excellent; the price is low; in this way, the herbal medicine is especially fit for people living in remote villages far away from counties and towns; the curing expense for patients with the adhesive ileus is low which solves the problem that the household income is low and the life is poor and the medical conditions is deficient locally.

The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and/or long term regulation of energy balance, short-, medium-, and/or long term regulation (stimulation and/or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and/or obesity, body weight gain and/or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

The invention relates to a Chinese medicinal composition for treating intestinal obstruction. The Chinese medicinal composition consists of the following Chinese medicinal raw materials in part by weight: 5 to 25 parts of immature bitter orange, 5 to 25 parts of officinal magnolia bark, 3 to 10 parts of rhubarb, 5 to 20 parts of dwarf lilyturf tuber, 5 to 25 parts of scrophularia root, 5 to 25 parts of rehmannia root, 10 to 40 parts of Chinese dwarf cherry seed, 10 to 40 parts of hemp fruit, 3 to 8 parts of liquoric root, 5 to 20 parts of tangerine peel and 10 to 40 parts of largehead atractylodes rhizome. The Chinese medicinal composition has the effects of depressing qi and inducing diuresis, relaxing bowel, relieving stagnant qi and removing qi stagnation, clearing heat and detoxicating and cooling blood and removing blood stasis, and has an obvious curative effect on intestinal obstruction and a reliable effect. The Chinese medicinal composition is wide in medicinal source, easy and convenient to prepare and mild in medicinal properties and does not have toxic or side effect.

Techniques are discloded for treating or reducing sumptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of one or more protease, antibacterial compound, and inflammatory lipid mediator.

The invention relates to stemona root alkaloid monomer components and applications thereof. The stemona root alkaloid monomer components are stenin, neostenine, sessilifoline B, and neotuberostemonin, and are used for preparing acetylcholinesterase inhibitors. The invention relates to the applications of the stemona root alkaloid monomer components in preparing medicines used for preventing and treating Alzheimer's disease, bowel obstruction, myasthenia gravis, or glaucoma. The stemona root alkaloid monomer components can also be used for preparing medicines used for improving intelligence.

The invention discloses a Chinese medicament for treating intestinal obstruction, which consists of the following raw material medicaments in part by weight: 1 to 3 parts of Chinese tumion seed, 1 to 3 parts of radish seed, 1 to 3 parts of Szechwan chinaberry fruit, 1 to 3 parts of dark plum fruit, 1 to 3 parts of areca seed, 1 to 3 parts of rangooncreeper fruit, 1 to 3 parts of Indian buead, 1 to 3 parts of tangerine peel, 1 to 3 parts of malt, 1 to 3 parts of officinal magnolia bark, 3 to 5 parts of immature bitter orange, 3 to 5 parts of rhubarb, 3 to 5 parts of costustoot, 3 to 5 parts of dahurian patrinia herb, 3 to 5 parts of Chinese angelica, 3 to 5 parts of cooked rehmannia, 3 to 5 parts of medcinal evodia fruit, 3 to 5 parts of red paeony root, 3 to 5 parts of doubleteeth pubescent angilica root and 3 to 5 parts of dahurian angelica root. The Chinese medicament for treating the intestinal obstruction has the effects of freeing interior and offensively precipitating, activating blood and dissolving stasis, clearing heat and detoxicating, resisting bacteria, promoting enterokinesis, accelerating inflammation absorption, assisting obstruction alleviating, and promoting absorption of inflammation adhesion of patients with the intestinal obstruction so as to achieve the purpose of treatment. The Chinese medicament comprises pure Chinese medicinal components, has the characteristics of reasonable formula, simple and convenient medication, obvious treatment effect and the like, and has a total effective rate of 93 percent in clinical application.

An adjustable size balloon at the distal end of a feeding tube is used to aid in positioning, along with an endoscope, the tube in the jejunum or small bowel of a patient, without creating an obstruction in the intestines. The balloon is fully inflated when the endoscope that is used to place the tube in the duodenum is withdrawn, and then partially deflated to a size that allows peristaltic action on the balloon to move the tube into the jejunum, after which the balloon is further deflated to avoid creating an obstruction in the intestine.

A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being exposed substantially only to the host's subcutaneous tissue layer. This orientation allows the tissue-ingrowth biodegradable region to become firmly incorporated with the host's body tissue. The adhesion-resistant biodegradable region faces the internal organs and decreases the incidence of adhesions and/or bowel obstruction.

The invention discloses a traditional Chinese medicine capsule for treating intestinal obstruction. The uppermost clinical symptoms of the intestinal obstruction are abdominal pain, vomit, abdominal distension and stop of exhaust defecation. The intestinal obstruction is great in harm, serious in disease, and high in mortality. By adopting the capsule, gas and blockages in intestinal tracts can be sprayed and discharged within 20-40 minutes, so that a sufferer can immediately take a turn to be out of danger; most of sufferers do not need to have an operation except for a few of sufferers needing to have an operation at once due to local intestinal necrosis or shock caused by delay of treatment time. The settle scheme of the traditional Chinese medicine capsule is that the traditional Chinese medicine capsule is prepared from the following traditional Chinese medicines in parts by weight: 20-30 parts of scutellaria baicalensis, 10-20 parts of coptis chinensis, 10-60 parts of rheum officinale, 10-50 parts of sodium sulfate and 1-3 parts of borneol.